BURNETT JOSEPH 4

What Happened
Joseph M. Burnett, CEO, President and a director of ClearPoint Neuro (CLPT), exercised options on 2026-03-19 to acquire 20,942 shares at an exercise price of $3.24 per share, for a cash outlay of $67,852. The Form 4 also shows a corresponding derivative conversion entry (20,942 shares at $0.00), which represents the option-to-stock conversion — no shares were sold.

Key Details

• Transaction date: March 19, 2026 (reported on Form 4 filed March 20, 2026). Filing appears timely.
• Transaction type/code: Exercise of stock options (Form 4 code M).
• Shares acquired: 20,942 common shares at $3.24 per share; total cash paid $67,852.
• Derivative conversion: a $0.00 “disposed” line reflects conversion of the option into common stock, not a market sale.
• Shares owned after transaction: The filing does not state a total post-transaction share count; the newly acquired shares are held by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Burnett as trustee (Footnote F2).
• Footnotes of note: (F1) Burnett paid the exercise price in cash and retained all shares received; no shares were sold. (F3) The underlying option grant (dated July 9, 2020) vested 20% at year one, 40% at year two and 40% at year three.

Context
This was an exercise of previously granted options (not a cashless exercise or sale): Burnett paid cash to convert options into common shares and kept the shares. Because the grant date was July 9, 2020 with a three‑year vesting schedule, those options would have been fully vested by mid‑2023. Exercises like this reflect conversion of equity compensation into stock and are procedural rather than an outright buy signal or sale by the insider.